JACKSONVILLE, Fla.–(BUSINESS WIRE)–NovaBone Products, a medical device company, today announces the U.S. Food and Drug Administration’s (FDA) approval of theNovaBone Putty® MIS Delivery System designed for use in minimally invasive orthopedic procedures.
The new system is characteristic of NovaBone Products’ ability to develop medical device technology designed for the unique needs of orthopedic surgeons. The NovaBone MIS Delivery System improves conventional delivery methods of bone graft substitutes through a syringe pre-loaded with ready-to-use NovaBone Putty and 6mm diameter cannulas at varying lengths. The system was developed for surgeons who require controlled and precise delivery of bone grafting material to the surgical site.
The NovaBone Putty MIS Delivery System delivers an osteoconductive matrix while signaling and stimulating osteoblastic activity to the orthopedic surgical site.
The product is approved for use in orthopedic surgeries of the extremities, the pelvis and posterolateral spine.
“The launch of the MIS Delivery System will be just the beginning of products our company will be offering to spine surgeons, neurosurgeons and orthopedic surgeons,” said Art Wotiz, President of NovaBone Products. “As a growing medical device company, we will introduce a number of new products this year and through 2011 that are based on advancements in bioengineered medical technology.”
New products will represent patented medical technology that will keep NovaBone Products in the forefront of the marketplace with orthopedic bone graft options.
NovaBone Products manufactures the NovaBone medical device brand of orthopedic bone graft products and is headquartered in Jacksonville with operations in Alachua, Florida. The company is dedicated to delivering novel bone graft substitutes based on biomedical engineering that meet the specialized needs of orthopedic surgeons.
